| Trial ID: | L0429 |
| Source ID: | IRCT20121216011763N47
|
| Associated Drug: |
Curcumin
|
| Title: |
The effects of curcumin plus piperine supplementation on cardiometabolic risk factors and fibroscan findings in patients with non-alcoholic steatohepatitis (NASH): a randomized doubleblind placebo-controlled trial
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic steatohepatitis (NASH). <br>Abnormal results of liver function studies;R94.5
|
| Interventions: |
Intervention 1: Intervention group: A daily curcumin-piperine capsule(500 mg curcumin+ 5 mg piperine) will receive after meal for 12 weeks. Intervention 2: Control group: A daily placebo capsule(500 mg maltodextrin) will receive after meal for 12 weeks.
|
| Outcome Measures: |
Triglyceride (TG). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Total Cholesterol (TC). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Low density lipoprotein (LDL). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;High density lipoprotein (HDL). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Digital scale.;Waist Circumference (WC). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Non-stretching tape measure.;Body mass index (BMI). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Dividing the weight into kilograms by squared height by meter.;Aspartate aminotransferase (AST). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;Alanine aminotransferase (ALT). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;Hepatic steatosis and fibrosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.;Fasting blood sugar (FBS). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic.;Blood pressure. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Sphygmomonometer.;Serum levels of High sensitive C-reactive protein (Hs-CRP). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.nan
|
| Sponsor/Collaborators: |
Esfahan University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 years65 years
|
| Phases: |
Not applicable
|
| Enrollment: |
60
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomly, based on the permuted block randomization method, using blocks of 4 that will be blocked based on gender var
|
| Start Date: |
14/05/2020
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
15 June 2020
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/47332
|
